Tags

Type your tag names separated by a space and hit enter

Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Future Oncol 2018; 14(11):1117-1132FO

Abstract

Despite the efficacy of standard-of-care EGFR tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib and afatinib, in EGFR mutation-positive non-small-cell lung cancer, resistance develops, most commonly due to the T790M mutation. Osimertinib showed clinical activity in the treatment of T790M-positive disease following progression on a first-line TKI, and is approved in this setting. Recently, osimertinib improved efficacy versus first-generation TKIs (erlotinib and gefitinib) in the first-line setting. Multiple factors can influence first-line treatment decisions, including subsequent therapy options, presence of brain metastases and tolerability, all of which should be considered in the long-term treatment plan. Further research into treatment sequencing is also needed, to optimize outcomes in EGFR mutation-positive non-small-cell lung cancer.

Authors+Show Affiliations

Thoracic Oncology, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, 69622, France. Thoracic Surgery, Institut Curie, Institut du Thorax Curie-Montsouris, Paris, 75248, France.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29336166

Citation

Girard, Nicolas. "Optimizing Outcomes in EGFR Mutation-positive NSCLC: Which Tyrosine Kinase Inhibitor and When?" Future Oncology (London, England), vol. 14, no. 11, 2018, pp. 1117-1132.
Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncol. 2018;14(11):1117-1132.
Girard, N. (2018). Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncology (London, England), 14(11), pp. 1117-1132. doi:10.2217/fon-2017-0636.
Girard N. Optimizing Outcomes in EGFR Mutation-positive NSCLC: Which Tyrosine Kinase Inhibitor and When. Future Oncol. 2018;14(11):1117-1132. PubMed PMID: 29336166.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? A1 - Girard,Nicolas, Y1 - 2018/01/16/ PY - 2018/1/18/pubmed PY - 2018/10/6/medline PY - 2018/1/17/entrez KW - EGFR KW - T790M KW - afatinib KW - dacomitinib KW - erlotinib KW - gefitinib KW - non-small-cell lung cancer KW - osimertinib KW - resistance KW - treatment sequencing SP - 1117 EP - 1132 JF - Future oncology (London, England) JO - Future Oncol VL - 14 IS - 11 N2 - Despite the efficacy of standard-of-care EGFR tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib and afatinib, in EGFR mutation-positive non-small-cell lung cancer, resistance develops, most commonly due to the T790M mutation. Osimertinib showed clinical activity in the treatment of T790M-positive disease following progression on a first-line TKI, and is approved in this setting. Recently, osimertinib improved efficacy versus first-generation TKIs (erlotinib and gefitinib) in the first-line setting. Multiple factors can influence first-line treatment decisions, including subsequent therapy options, presence of brain metastases and tolerability, all of which should be considered in the long-term treatment plan. Further research into treatment sequencing is also needed, to optimize outcomes in EGFR mutation-positive non-small-cell lung cancer. SN - 1744-8301 UR - https://www.unboundmedicine.com/medline/citation/29336166/Optimizing_outcomes_in_EGFR_mutation_positive_NSCLC:_which_tyrosine_kinase_inhibitor_and_when L2 - http://www.futuremedicine.com/doi/full/10.2217/fon-2017-0636?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -